Dergiler / BEYOGLU EYE JOURNAL / 2021 / Cilt: 6 - Sayı: 2

Effects of Intravitreal Injection on Ocular Surface and Anterior Segment Parameters

Sayfa
84–89
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Intravitreal anti-VEGF injections had no effect on ocular surface, corneal endothe-lium, and anterior segment parameters.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: This study was designed to investigate the long-term effects of intravitreal anti-vascular endothelial growth factor (VEGF) injections on ocular surface and anterior segment parameters.
📊
Temel Bulgular & Veri:Methods: The study group included patients who had received at least 3 intravitreal injections of anti-VEGF agents (bevacizumab, ranibizumab, or aflibercept) for retinal vascular disorders.
💡
Sonuç & Katkı:Conclusion: Intravitreal anti-VEGF injections had no effect on ocular surface, corneal endothe-lium, and anterior segment parameters.
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: This study was designed to investigate the long-term effects of intravitreal anti-vascular endothelial growth factor (VEGF) injections on ocular surface and anterior segment parameters. A comparison was performed of the treated eye and the fellow healthy eye. Methods: The study group included patients who had received at least 3 intravitreal injections of anti-VEGF agents (bevacizumab, ranibizumab, or aflibercept) for retinal vascular disorders. All of the subjects were treated in only 1 eye. A complete ophthalmological examination, including evaluation of tear break-up time (TBUT), the Schirmer 1 test, the Oxford Grading Scale, and the Ocular Surface Disease Index (OSDI) questionnaire, corneal topography, and specular microscopy were performed in both eyes 1 month after the last injection. Results: In this study, 49 eyes of 49 patients who underwent regular intravitreal injection in 1 eye were enrolled. The mean age was 63.85±9.8 years (range: 29-86 years). A mean of 4.06±1.7 (range: 3-11) injections were administered. There was no significant difference in the intraocular pressure, TBUT, Schirmer 1, fluorescein staining, or specular microscopy parameters (p>0.05). The mean non-invasive TBUT first and average values; the central, thinnest, and apex corneal thickness measurements; the anterior chamber depth, irido-corneal angle, corneal volume, and keratometry values were similar in each individual (p>0.05 for all parameters). The mean OSDI score was 27.5±17.6 for the injected eyes and 15.9±12.9 for the non-injected eyes (p<0.0001). Conclusion: Intravitreal anti-VEGF injections had no effect on ocular surface, corneal endothe-lium, and anterior segment parameters.

🔖

Bu Makaleye Atıf Yap

ULUTAŞ, H. G., YENER, N. P. (2021). Effects of Intravitreal Injection on Ocular Surface and Anterior Segment Parameters. BEYOGLU EYE JOURNAL, Cilt: 6 - Sayı: 2, 84–89. https://ajindex.com/articles/396509

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Campell RJ, Bronskill SE, Bell CM, Paterson MJ, Whitehead M, Gill SS. Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis. Arch Ophthalmol 2010;128:359–62
  2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al; MARINA Study Group. Ranibizumab for neovascular age related macular degeneration. N Engl J Med 2006;355:1419– 31
  3. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR Study Group. Ranibizumab versus verteporfirin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–44
  4. Falavarjani KG, QD Nguyen. Adverse events and complications associated with in-travitreal injection of anti-VEGF agents: a review of literature. Eye 2013;27:787–94
  5. Ridder WH, Oquindo C, Dhamdhere K, Burke J. Effect of povidone iodine 5% on the cornea, vision, and subjective comfort. Optom Vis Sci 2017;94:732–41
  6. Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: 400 The good, the bad and the ugly. Prog Retin Eye Res 2010;29:312–34
  7. Zhang R, Park M, Richardson A, Tedla N, Pandzic E, Paiva CS, et al. Dose-dependent benzalkonium chloride toxicity imparts ocular surface epithelial changes with features of dry eye disease. Ocul Surf 2020;18:158–69
  8. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 2007;5:75–92
  9. Miljanovic B, Dana R. Impact of dry eye syndrome on visionrelated quality of life. Am J Ophthalmol 2007;143:409–15
  10. Yeh S, Song XJ, Farley W, Li DQ, Stern ME, Pflugfelder SC. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest Ophthalmol Vis Sci 2003;44:124–9
  11. Calonge M, Salamanca EA, Diebold Y, Garcia MJG, Reinoso R, Herreras JM, et al. Dry eye disease as an inflammatory disorder. Ocul Immunol Inflamm 2010;18:244–53
  12. Dohlman TH, Lertsuwanroj B, D’Amico DJ, Ciralsky JB, Kiss S. Evaluation of signs and symptoms of ocular surface disease after intravitreal injection. Acta Ophthalmol 2019;97:1154–6
  13. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22:640–50
  14. Seadon H, Nosek J, Phillips J, Narendran N, Yang YC. Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections. Cutan Ocul Toxicol 2017;36:343–6
  15. Srinagesh V,